Search General Info
Search Education
Search Partnering Companies
Phanes Therapeutics, Inc.
11:30 AM - 11:45 AM (EDT), Thursday, June 8, 2023 ・ Session Room 103
![BIO International Convention](/sites/default/files/2021-09/_BIO_CONV_Logo-White.png)
Phanes is a clinical stage biotech focused on innovative drug discovery and development in oncology. Currently, it has three assets at clinical stage, its best-in-class monoclonal antibody (mAb) program, PT199, and two first-in-class bispecific antibody programs, PT886 and PT217. Both PT886 and PT217 have been granted orphan drug designation by FDA. Its pipeline also includes humanized mAbs, biparatopics, and single-chain variable fragments (scFvs) against multiple tumor-associated antigens (TAAs) that are suitable for ADC and CAR-T applications, respectively.
The company has three proprietary technology platforms: PACbody™, for constructing bispecific antibodies that maintain native structures with superb CMC characteristics; SPECpair™ allows mAb-like manufacturability of bispecific antibodies with native IgG-like structures,; and ATACCbody™ for modulated activities designed to minimize the risk of cytokine release syndrome.
The company has three proprietary technology platforms: PACbody™, for constructing bispecific antibodies that maintain native structures with superb CMC characteristics; SPECpair™ allows mAb-like manufacturability of bispecific antibodies with native IgG-like structures,; and ATACCbody™ for modulated activities designed to minimize the risk of cytokine release syndrome.
![](https://www.abstractscorecard.com/uploads/Tasks/upload/20525/EOISBJNL-1539229-1-JPG.png)
Ticker:
Not Provided
Exchange:
Not Provided
Company Type:
Not Provided
Company Website:
Company HQ State:
CA
Company HQ Country:
United States
Year Founded:
2016
Main Therapeutic Focus:
Oncology
Lead Product in Development:
PT199 - anti-CD73 antibody
PT886 - anti-claudin18.2/anti-CD47 bispecific antibody
PT217 - anti-DLL3/anti-CD47 bispecific antibody
Development Phase of Primary Product:
Phase I
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
![](https://www.conferenceharvester.com/uploads/harvester/photos/EOISBJNL-Presenter-ChuP.jpg)
BIO DOUBLE HELIX SPONSORS
![Sanofi logo](/sites/default/files/2022-05/Sanofi_Color_jpg_Double%20Helix.jpg)
![Eli Lilly and Company](/sites/default/files/2019-09/Eli%20Lilly%20and%20Company.png)
![Amgen logo](/sites/default/files/2022-05/Amgen_Color_png_Double%20Helix.png)
![Genentech logo](/sites/default/files/2022-05/Genentech_Color_png_Double%20Helix.png)
![Merck_logo_2022](/sites/default/files/2022-10/Merck_Color_.png)
![Avantor](/sites/default/files/2021-06/Avantor-BIO-DH-578.png)
![GSK logo](/sites/default/files/2023-04/gsk_color_png.png)
BIO HELIX SPONSORS
![Johnson and Johnson](/sites/default/files/2021-06/Johnson-Johnson-BIO-DH-578.png)
![Takeda logo](/sites/default/files/2022-05/Takeda_Color_jpg_Premier.jpg)
![Travere logo](/sites/default/files/2022-05/Travere_Color_png_Helix%20large.png)
1201 New York Avenue NW, Suite 1300, Washington, DC, 20005 ・ 202-962-9200
© BIO 2024 All Rights Reserved